These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36267752)

  • 1. Combination of Type I and II tyrosine kinase inhibitors-avapritinib and sunitinib-in refractory gastrointestinal stromal tumor after failure to multi-line therapy: a case report.
    Guo X; Huang S; Shi Y; Guan Z; Chen S; Feng Y; Xia Y; Zhang X
    Ann Transl Med; 2022 Sep; 10(18):1026. PubMed ID: 36267752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
    Zalcberg JR
    Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review.
    Zhang Y; Huang Z
    Front Pharmacol; 2023; 14():1122885. PubMed ID: 37288114
    [No Abstract]   [Full Text] [Related]  

  • 4. Progression of the tumor in a patient with a gastrointestinal stromal tumor with the
    An Z; Tan M; Xia Y; Li Y; Fan L; Zhao Q; Zhang Z; Tan B; Liu Y; Ma Z; Wang D; Zhao X
    J Gastrointest Oncol; 2022 Oct; 13(5):2620-2625. PubMed ID: 36388657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
    Senchak J; Ahr K; von Mehren M
    Curr Treat Options Oncol; 2022 May; 23(5):749-761. PubMed ID: 35349049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fourth-line rescue treatment ripretinib of advanced small intestine gastrointestinal stromal tumors who achieved partial response: a case report.
    Liu B; Kou Y
    J Gastrointest Oncol; 2022 Jun; 13(3):1505-1513. PubMed ID: 35837161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M; Gelderblom H
    Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
    [No Abstract]   [Full Text] [Related]  

  • 8. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
    Bauer S; George S; von Mehren M; Heinrich MC
    Front Oncol; 2021; 11():672500. PubMed ID: 34322383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical Management of Metastatic Gastrointestinal Stromal Tumors.
    Yonkus JA; Alva-Ruiz R; Grotz TE
    Curr Treat Options Oncol; 2021 Mar; 22(5):37. PubMed ID: 33743084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
    Huang WK; Wu CE; Wang SY; Chang CF; Chou WC; Chen JS; Yeh CN
    Curr Treat Options Oncol; 2022 Sep; 23(9):1303-1319. PubMed ID: 35976553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
    Symcox M; Jones RL
    Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report.
    Huang S; Guo X; Xia Y; Ding L; Zhai E; Chen S; He Y; Cai S; Zhang X
    Ann Transl Med; 2022 Jan; 10(2):118. PubMed ID: 35282043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
    Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fourth-line targeted drugs for the long-term treatment of patients with secondary gastrointestinal stromal tumors with multisite mutations: a case report.
    Zhang N; Wu X; Xu W; Chen L; Tu X
    Ann Palliat Med; 2023 Jan; 12(1):227-235. PubMed ID: 36747392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
    Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S
    Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for the treatment of gastrointestinal stromal tumors.
    Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical model-based evaluation of Imatinib resistance induced by
    Zhao Q; Zhang C; Qi C; Yang J; Chen Y; Ge S; Shen L; Gao J; Li J
    Am J Transl Res; 2021; 13(12):13608-13624. PubMed ID: 35035701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.
    Patel SR; Reichardt P
    Cancer; 2021 Jul; 127(13):2187-2195. PubMed ID: 33974733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates.
    Farag S; Smith MJ; Fotiadis N; Constantinidou A; Jones RL
    Curr Treat Options Oncol; 2020 May; 21(7):55. PubMed ID: 32462367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New frontiers in the medical management of gastrointestinal stromal tumours.
    Mazzocca A; Napolitano A; Silletta M; Spalato Ceruso M; Santini D; Tonini G; Vincenzi B
    Ther Adv Med Oncol; 2019; 11():1758835919841946. PubMed ID: 31205499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.